Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody–Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk
Authors' conclusion
Anti-Ro52 antibodies were highly prevalent in patients with anti-MDA5+ DM, and their coexistence correlated with a higher rate of RP-ILD and mortality.
Study context
- Population
- Patients with anti-MDA5+ dermatomyositis (DM); 70 male, average age 53.1 (12.4) years
- Participants
- 246 patients
- Exposure
- Anti-Ro52-positive vs anti-Ro52-negative anti-MDA5+ DM
- Anti-Ro52+n = 158
- Outcome
- RP-ILD and death
Methodological detailsunivariate and multivariate Cox regression, stepwise forward selection
- Univariate and multivariate Cox regression
- Stepwise forward selection
Main finding
As reported in the abstract
- Anti-Ro52+ vs Anti-Ro52−: log-rank P < 0.001
- Anti-Ro52+ vs Anti-Ro52−: log-rank P = 0.01
Observational data: associations, not effects.
Further findings
- Prevalence of anti-Ro52 — Anti-Ro52+
- 64.2%
- Prevalence of anti-Ro52: 158/246
Risk factors in anti-Ro52+ patients
- Short disease course and high inflammation: increased risk of rapidly progressive ILD (RP-ILD) and death
- Active rash: independent protective factor of death
Original publication
Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody–Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk. J Rheumatol. Published 15 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →